These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29083137)

  • 1. Efficacy and acceptance of the sacral neuromodulation in the treatment of female lower urinary tract dysfunctions.
    Adile B; Speciale P; Gugliotta G; Consiglio P; Manzone M; Adile G; Saitta S; Perino A; Calagna G
    Minerva Ginecol; 2018 Apr; 70(2):236-238. PubMed ID: 29083137
    [No Abstract]   [Full Text] [Related]  

  • 2. Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience.
    Chartier-Kastler E
    BJU Int; 2008 Feb; 101(4):417-23. PubMed ID: 18070181
    [No Abstract]   [Full Text] [Related]  

  • 3. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
    Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pulse rate changes on the clinical outcome of sacral neuromodulation.
    Marcelissen TA; Leong RK; Nieman FH; de Bie RA; van Kerrebroeck PE; de Wachter SG
    J Urol; 2011 May; 185(5):1781-5. PubMed ID: 21420118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
    Fletcher N
    Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome?
    Jairam R; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    Neuromodulation; 2017 Dec; 20(8):830-835. PubMed ID: 28877395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
    Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
    Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.
    Tahseen S
    Int Urogynecol J; 2018 Aug; 29(8):1081-1091. PubMed ID: 29302716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention.
    Penson DF
    J Urol; 2016 Mar; 195(3):689. PubMed ID: 26887733
    [No Abstract]   [Full Text] [Related]  

  • 11. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
    Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
    World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Supervised 3 Weeks Test Phase in Sacral Neuromodulation with a 1-Year Followup.
    Tilborghs S; Van de Borne S; Vaganée D; De Win G; De Wachter S
    J Urol; 2021 Jan; 205(1):206-212. PubMed ID: 32716692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.
    Jairam R; Drossaerts J; van Koeveringe G; van Kerrebroeck P
    Urol Int; 2017; 99(1):51-55. PubMed ID: 28478446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sacral neuromodulation and sexuality].
    Gamé X
    Prog Urol; 2008 Mar; 18(3):167. PubMed ID: 18472069
    [No Abstract]   [Full Text] [Related]  

  • 16. What Is New in Neuromodulation?
    Moore CK; Rueb JJ; Derisavifard S
    Curr Urol Rep; 2019 Aug; 20(9):55. PubMed ID: 31388779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromodulation and female pelvic disorders.
    Noblett K
    Curr Opin Urol; 2016 Jul; 26(4):321-7. PubMed ID: 27070647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of sacral neuromodulation with the tined lead procedure.
    Marcelissen TA; Leong RK; de Bie RA; van Kerrebroeck PE; de Wachter SG
    J Urol; 2010 Nov; 184(5):1997-2000. PubMed ID: 20850820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral Neuromodulation: Device Improvement and Current Applications in Urology.
    Spilotros M; Gerbasi S; Lasorsa F; de Rienzo G; Balducci L; Ditonno P; Lucarelli G
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Factors in Sacral Neuromodulation: A Systematic Review.
    Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; Vrijens D; van Kerrebroeck P
    Urol Int; 2022; 106(4):323-343. PubMed ID: 34058731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.